ArticleEuropean radiology2026
Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
Abstract
objectivesTo evaluate the prognostic significance of whole-body diffusion-weighted imaging (WBDWI)-derived metrics, including total diffusion volume (TDV) and global apparent diffusion coefficient (gADC), in patients with metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND
methodsThis retrospective single-centre study included patients with mCRPC and bone-predominant disease who underwent whole-body MRI (WBMRI) prior to the start of a new treatment. Bone lesions were segmented on b900 DWI using an AI-assisted tool with radiologist refinement, and TDV and gADC were extracted. Automated bone scan index (aBSI) was calculated when bone scintigraphy was available. Clinical and laboratory parameters were recorded. Overall survival (OS) was the primary endpoint. Kaplan-Meier analysis and Cox regression models were used to assess prognostic associations.
resultsAmong 360 patients, higher TDV was associated with significantly shorter OS (median OS: 13.2 vs 33.4 months; p < 0.001), whereas gADC showed no significant association. In multivariable analysis including patients with WBMRI and bone scintigraphy (n = 182), log-TDV (HR 1.20; p = 0.027), LDH > 500 U/L (HR 7.79; p < 0.001) and ALP between 200 and 400 U/L (HR 1.78; p = 0.019) were independently associated with OS, while aBSI was not. In patients without aBSI data (n = 85), log-TDV remained prognostic (HR 1.60; p < 0.001), whereas LDH and ALP were not.
conclusionTDV derived from WBDWI independently predicts OS in mCRPC and demonstrates stronger prognostic performance than aBSI and conventional laboratory markers in multivariable models, whereas gADC was not prognostic. KEY POINTS: QuestionThere is no widely adopted quantitative imaging biomarker for prognostic stratification in mCRPC. Can whole-body diffusion-weighted MRI-derived metrics improve prognostic risk stratification in patients with bone metastases? FindingsHigher TDV of bone disease on baseline whole-body diffusion-weighted MRI was independently associated with shorter OS in patients with mCRPC. Clinical relevance Whole-body diffusion-weighted MRI-derived tumour volume may provide a practical quantitative imaging biomarker for prognostic stratification in mCRPC, potentially supporting individualised treatment planning.
Indexed as
Identifiers
42593500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.